ARBS Stock Overview
A research-based biotech company, engages in the research and development of various ingredients and natural solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Arterra Bioscience S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.04 |
| 52 Week High | €2.40 |
| 52 Week Low | €1.48 |
| Beta | 1.06 |
| 11 Month Change | 5.15% |
| 3 Month Change | 3.03% |
| 1 Year Change | 31.61% |
| 33 Year Change | -40.00% |
| 5 Year Change | -58.79% |
| Change since IPO | -40.20% |
Recent News & Updates
Shareholder Returns
| ARBS | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 5.7% | 0.9% | -0.6% |
| 1Y | 31.6% | 7.5% | 12.2% |
Return vs Industry: ARBS exceeded the Italian Biotechs industry which returned 7.6% over the past year.
Return vs Market: ARBS exceeded the Italian Market which returned 11.9% over the past year.
Price Volatility
| ARBS volatility | |
|---|---|
| ARBS Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.1% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: ARBS has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: ARBS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Maria Colucci | www.arterrabio.it |
Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. It develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. Arterra Bioscience S.p.A. was founded in 2003 and is based in Napoli, Italy.
Arterra Bioscience S.p.A. Fundamentals Summary
| ARBS fundamental statistics | |
|---|---|
| Market cap | €13.58m |
| Earnings (TTM) | €1.34m |
| Revenue (TTM) | €3.64m |
10.1x
P/E Ratio3.7x
P/S RatioIs ARBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARBS income statement (TTM) | |
|---|---|
| Revenue | €3.64m |
| Cost of Revenue | €1.62m |
| Gross Profit | €2.03m |
| Other Expenses | €682.79k |
| Earnings | €1.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 55.64% |
| Net Profit Margin | 36.90% |
| Debt/Equity Ratio | 3.2% |
How did ARBS perform over the long term?
See historical performance and comparison